Say goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaq
Eight months after Vallon Pharmaceuticals’ late-stage shot at R&D glory ended in a short, sharp implosion with the failure of a Phase III study for its lead ADHD drug, the tiny biotech will hand over its public listing in a reverse merger that will shove a low-profile NKT cell player into the public arena.
Vallon $VLON will now disappear under the storm-tossed seas of Nasdaq, as GRI Bio in San Diego tries its hand at drug development as a public company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
